Table 1.
Clinical and demographic characteristics of patients and controls
| Characteristic | Patients (n = 456) | Controls (n = 495) |
|---|---|---|
| Mean agea (years) ± SD | 52.4 ± 9.8 | 51.9 ± 10.2 |
| Tumor stage, n (%) | ||
| IA | 61 (13.4) | |
| IB | 63 (13.8) | |
| IIA | 59 (12.9) | |
| IIB | 55 (12.1) | |
| IIIA | 148 (32.5) | |
| IIIB | 53 (11.6) | |
| IVA | 9 (2.0) | |
| IVB | 8 (1.7) | |
| Histologic grade, n (%) | ||
| G1 | 87 (19.1) | |
| G2 | 145 (31.8) | |
| G3 | 98 (21.5) | |
| Gx | 126 (27.6) | |
| Histologic type, n (%) | ||
| Squamous cell carcinoma | 384 (84.2) | |
| Adenocarcinoma | 56 (12.3) | |
| Other | 16 (3.5) | |
| Parity , n (%) | ||
| Never | 51 (11.2) | 56 (11.31) |
| Ever | 405 (88.8) | 439 (88.6) |
| Oral contraceptive pill use, n (%) | ||
| Never | 248 (54.4) | 278 (56.2) |
| Ever | 208 (45.6) | 217 (43.8) |
| Tobacco smoking, n (%) | ||
| Never | 295 (64.7) | 331 (66.9) |
| Ever | 161 (35.3) | 164 (33.1) |
| Menopausal status, n (%) | ||
| Premenopausal | 159 (34.9) | 190 (38.4) |
| Postmenopausal | 297 (65.1) | 305 (61.6) |
| HPV genotypesb, n (%) | ||
| 16 and 18 | 311 (68.2) | |
| 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 | 352 (77.2) | |
aAge at first diagnosis
bHPV genotypes were determined by Cobas® HPV Test Roche Molecular Systems, Inc. (Alameda, CA, USA)
HPV human papilloma virus, SD standard deviation